Feasibility of using collagen as the base of the antifungal drug, miconazole

Journal of Oral Rehabilitation
K YoshidaY Igarashi

Abstract

The feasibility of using collagen as the base of miconazole was investigated. The addition of 33% collagen to a miconazole solution did not affect the minimal inhibitory concentration (MIC80) of the miconazole solution for Candida albicans. When 1 microg mL(-1) of miconazole in 33% collagen solution was plated on resin discs and dried to yield a thin membrane, the growth of C. albicans on the resin discs was nearly completely inhibited. In addition, we compared the antifungal effect of this collagen solution that contained 1 microg mL(-1) miconazole, with the antifungal effect of miconazole gel that had been diluted with glycerol (the main component of miconazole gel) to yield a final concentration of 1 microg mL(-1) of miconazole; as a result, we found that the collagen solution containing 1 microg mL(-1) miconazole had a stronger antifungal effect. In conclusion, our results demonstrated that it may be feasible to use collagen as the base of miconazole instead of glycerol, and suggest that a collagen-based miconazole solution would have a stronger antifungal effect than commercially available miconazole gel. Collagen-based miconazole solution may be useful for the treatment of Candida-associated denture stomatitis.

References

Oct 1, 1976·Australian Dental Journal·R J Bastiaan
Apr 1, 1992·Australian Dental Journal·S Jeganathan, C C Lin
Jan 1, 1991·European Journal of Epidemiology·G TronchinJ M Senet
May 1, 1989·Journal of Dental Research·R J Gibbons
Jan 1, 1985·Journal of Inherited Metabolic Disease·I SmithB Kendall
Mar 1, 1970·Acta Odontologica Scandinavica·E Budtz-Jorgensen, U Bertram
Jun 15, 1982·British Dental Journal·C J WatsonR G Newcombe
Dec 1, 1994·Scandinavian Journal of Dental Research·T ParvinenA Yli-Urpo
Aug 15, 1998·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·W Friess
Apr 19, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J H RexJ E Edwards
Jan 5, 2002·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Dieter SwatschekJörg Kreuter

❮ Previous
Next ❯

Citations

May 29, 2008·Future Microbiology·Andrei Barasch, Andreea Voinea Griffin
Aug 19, 2007·Dental Materials Journal·Takeshi ShibataMinoru Toyoda
Aug 9, 2017·Philosophical Transactions. Series A, Mathematical, Physical, and Engineering Sciences·Oliver AndrewsParvadha Suntharalingam

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.